Unveiling CCL2 and CXCL1: Key biomarkers and therapeutic targets in idiopathic pulmonary fibrosis
Jing Pan, Guanhua Li, Yuanyuan Pu, Peilin Li, Yan Zhou · 2025
Read Unveiling CCL2 and CXCL1: Key biomarkers and therapeutic targets in idiopathic pulmonary fibrosis by Jing Pan, Guanhua Li, Yuanyuan Pu, Peilin Li, Yan Zhou (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12815301.txt.
Description
A lung disease that scars without a known cause needs molecular fingerprints. Jing Pan and four co-authors pulled two from the lung's own scavenger cells in a 2025 study of idiopathic pulmonary fibrosis. They mined a public dataset of alveolar macrophages from 23 patients and 61 healthy controls.
Two chemokines, CCL2 and CXCL1, stood out as sharply raised in the disease. Blood tests in a fresh cohort of 50 patients and 50 controls confirmed both run high in patients' serum. The higher they ran, the worse the patients' lung function measured. A third candidate, CCL7, failed to separate the groups. Enrichment analysis tied the changes to inflammation and matrix remodeling pathways. The authors propose the pair as biomarkers for tracking the disease and as targets worth drugging.
Catalog record
| CREATOR | Jing Pan, Guanhua Li, Yuanyuan Pu, Peilin Li, Yan Zhou |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |